Cairo - Mubasher: Memphis Pharmaceutical Co. reported its adjusted unaudited financial results for the fiscal year 2014/15, that reflected losses of EGP 10.3 million ($1.2 million) against profits of EGP 14,000 ($1,600) for the same previous year.

Meanwhile, the firm posted gross profits of EGP 382.2 million in FY14/15, compared with EGP 375.5 million in the preceding year.

The drug firm is capitalised at EGP 56.2 million, distributed across 5.6 million shares at EGP 10 par value each.